Heidi L.  Wagner net worth and biography

Heidi Wagner Biography and Net Worth

Director of WAVE Life Sciences

Heidi Wagner serves as Global Head of Government Affairs at ElevateBio, LLC, where she serves on the company’s executive team and is responsible for leading the company’s global government affairs function. Ms. Wagner serves as a member of the board of directors of the Lieber Institute for Brain Development, and as an advisory board member of the University of Colorado, College of Media, Communication and Information. Ms. Wagner also serves as a member of the board of directors and as a Trustee for the University of Colorado Foundation. From 2018 through January 2021, she served as Senior Vice President, Government Affairs and Policy at Global Blood Therapeutics, Inc., where she was responsible for developing and implementing comprehensive strategies related to health care policy and patient access. Throughout her career, she has held roles responsible for all aspects of government affairs and pricing, including overseeing a broad portfolio of legislative and regulatory policy issues at international, national, and local levels, and overseeing discussions relating to pricing, reimbursement, and patient access, as well as patient advocacy. Previously, Ms. Wagner served as Senior Vice President of Global Government Affairs at Alexion where she successfully led funding negotiations and global payor strategy in support of the company’s rare disease portfolio across its 50-country platform. She also held early leadership roles at Genentech, Inc., and the Healthcare Leadership Council. Ms. Wagner earned a JD at George Mason University School of Law and a BS in Journalism & Mass Communication from the University of Colorado, Boulder.

What is Heidi L. Wagner's net worth?

The estimated net worth of Heidi L. Wagner is at least $581.39 thousand as of December 8th, 2025. Wagner owns 44,930 shares of WAVE Life Sciences stock worth more than $581,394 as of January 31st. This net worth evaluation does not reflect any other investments that Wagner may own. Learn More about Heidi L. Wagner's net worth.

How do I contact Heidi L. Wagner?

The corporate mailing address for Wagner and other WAVE Life Sciences executives is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. WAVE Life Sciences can also be reached via phone at (656) 236-3388 and via email at [email protected]. Learn More on Heidi L. Wagner's contact information.

Has Heidi L. Wagner been buying or selling shares of WAVE Life Sciences?

Heidi L. Wagner has not been actively trading shares of WAVE Life Sciences within the last three months. Most recently, Heidi L. Wagner sold 14,000 shares of the business's stock in a transaction on Monday, December 8th. The shares were sold at an average price of $13.50, for a transaction totalling $189,000.00. Following the completion of the sale, the director now directly owns 44,930 shares of the company's stock, valued at $606,555. Learn More on Heidi L. Wagner's trading history.

Who are WAVE Life Sciences' active insiders?

WAVE Life Sciences' insider roster includes Paul Bolno (CEO), Mark Corrigan (Director), Chris Francis (insider), Christian Henry (Director), Kyle Moran (CFO), Adrian Rawcliffe (Director), Ken Takanashi (Director), Gregory Verdine (Director), and Heidi Wagner (Director). Learn More on WAVE Life Sciences' active insiders.

Are insiders buying or selling shares of WAVE Life Sciences?

In the last twelve months, WAVE Life Sciences insiders bought shares 1 times. They purchased a total of 1,470,000 shares worth more than $27,930,000.00. In the last twelve months, insiders at the sold shares 17 times. They sold a total of 1,363,535 shares worth more than $17,815,766.35. The most recent insider tranaction occured on January, 2nd when insider Chris Francis sold 9,375 shares worth more than $150,281.25. Insiders at WAVE Life Sciences own 24.0% of the company. Learn More about insider trades at WAVE Life Sciences.

Information on this page was last updated on 1/2/2026.

Heidi L. Wagner Insider Trading History at WAVE Life Sciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/8/2025Sell14,000$13.50$189,000.0044,930View SEC Filing Icon  
See Full Table

Heidi L. Wagner Buying and Selling Activity at WAVE Life Sciences

This chart shows Heidi L Wagner's buying and selling at WAVE Life Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

WAVE Life Sciences Company Overview

WAVE Life Sciences logo
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
Read More

Today's Range

Now: $12.94
Low: $12.75
High: $13.21

50 Day Range

MA: $14.03
Low: $6.99
High: $21.31

2 Week Range

Now: $12.94
Low: $5.28
High: $21.73

Volume

2,326,426 shs

Average Volume

4,587,866 shs

Market Capitalization

$2.16 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A